ADMA Biologics Lawsuit: Did 'Channel Stuffing' Create Phantom Growth?

RAMSEY, NJ – June 16, 2026 – A biopharmaceutical company once praised for its robust growth is now at the center of a securities fraud firestorm. ADMA Biologics, Inc. (NASDAQ: ADMA), a maker of specialty plasma-derived therapies, has been hit with a class action lawsuit alleging it orchestrated a “channel stuffing” scheme to fabricate its impressive 2025 revenue figures. The allegations, first leveled in a scathing report by short-seller Culper Research, sent the company’s stock into a nosedive, wiping out nearly 40% of its value in three days and leaving investors scrambling for answers ahead of an August 10 legal deadline.

The Anatomy of an Allegation

The crisis for ADMA Biologics ignited on March 24, 2026, when Culper Research published a report with a provocative title: "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported." The report claimed the company's celebrated 20% revenue growth was, in fact, "a fiction."

At the heart of the allegation is a practice known as channel stuffing, where a manufacturer pushes more product onto its distributors than they can realistically sell to end-users. This can prematurely inflate a company's reported revenue, creating a deceptive picture of market demand. Culper Research alleged that ADMA induced a key distributor to stockpile its flagship immune globulin product, ASCENIV, by offering incentives like rebates and extended payment terms. According to the short-seller, this scheme allowed ADMA to book sales and report growth that simply “was never there.” Culper’s analysis concluded that without this alleged manipulation, ADMA’s revenue would have actually declined by 3% in 2025.

The report also leveled accusations of a conflict of interest, claiming the existence of an "undisclosed related party transaction." It pointed to Genesis BioPharma Services, an entity allegedly controlled by ADMA's Vice Chairman and operating out of the company’s own headquarters, which was purportedly involved in transactions that were not disclosed to shareholders as such.

Market Meltdown and Investor Action

The market’s reaction was swift and brutal. On the day the Culper report was released, ADMA’s stock plunged 16.6%. The sell-off continued the next day with another 15% drop, followed by a further 13.9% decline after Investing.com reported that Cantor Fitzgerald had downgraded the stock from "Overweight" to "Neutral." The analyst firm reportedly cited concerns that ADMA’s initial response to the allegations lacked the specific details investors were seeking.

In the wake of this collapse, the legal machinery began to turn. Multiple law firms, including Bleichmar Fonti & Auld LLP, announced the filing of a securities fraud class action lawsuit in the U.S. District Court for the District of New Jersey. The suit, filed on behalf of investors who purchased ADMA securities between August 9, 2024, and March 25, 2026, alleges that the company and its senior executives violated federal securities laws by making materially false and misleading statements about its financial performance and internal controls. Investors wishing to be appointed as a lead plaintiff in the case have until August 10, 2026, to file with the court.

ADMA's Defense and Industry Context

ADMA Biologics has forcefully pushed back against the allegations. In public statements, the company characterized the short-seller report as containing "misleading, false and inaccurate statements" based on "speculative assertions from unidentified sources." The company insists that demand for its flagship product, ASCENIV, is "real and growing."

In its defense, ADMA has situated its inventory practices within the specific context of the biopharmaceutical industry. The company argues that for complex plasma-derived therapies like immune globulin, which have long and complex production cycles, it is standard for distributors to maintain significant safety stock to ensure uninterrupted supply for patients with chronic conditions. ADMA stated its distributor inventory levels were well within industry norms and that it had received "unqualified opinions" on its financial audits for both 2024 and 2025 from a Big Four accounting firm. It also flatly denied any undisclosed related-party product transactions.

Scrutiny on Governance and Transparency

The lawsuit and the events surrounding it shine a harsh light on the roles of both corporate governance and activist short-sellers in today's market. Firms like Culper Research, which openly holds a short position in ADMA stock and thus profits from its decline, position themselves as market watchdogs exposing fraud. However, their financial motives invariably draw scrutiny.

At the same time, the allegations have drawn attention to potential red flags in ADMA's corporate history. The lawsuit complaint notes the resignation of the company's long-time auditor in 2024. The legal action specifically names CEO Adam S. Grossman, Vice Chairman Jerrold V. Grossman, and former CFO Brad Tade as defendants, alleging they were responsible for signing SEC filings that contained the allegedly false statements about revenue growth and the effectiveness of the company’s internal controls.